the dose escalation question that gets asked weekly, answered properly
the dose escalation question that gets asked weekly, answered properly. Making the case below, and I expect to lose some of it in the comments. Stopped at a low step because there was no reason to go further and no data to tell me what further would do. The thing that surprised me was how much of the discussion here…
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
heart rate is the thing people report watching
the energy-expenditure story is mechanistically interesting and clinically unproven
phase 2 data only, and people quote it like it is a label
small trial, big effect, wide error bars
What the glucagon arm is doing, as best anyone can say from public data.
injection_site_iris is right about the escalation being the variable. It explains most of the difficult reports here.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.